Clinical trialNCT05285891RecruitingPhase 4Interventional

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment123Multiple Sclerosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, and 24. At Month 24, participants will be randomized (2:1) to one of two Arms with randomized treatment beginning at Month 30: Arm 1: placebo infusions every 6 months; or Arm 2: OCR infusions every 6 months. The treatment period will be for a total of 48 months.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Amit Bar-Or, M.D.
University of Pennsylvania, Perelman School of Medicine: Department of Neurology
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Yale School of Medicine
New Haven, Connecticut, United States
Erin Longbrake
Recruiting
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Benjamin Osborne, MD
Recruiting
Northwestern University
Chicago, Illinois, United States
Farrah Mateen, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Michael Levy, MD
Recruiting
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts, United States
Carolina Ionete
Recruiting
Rwj Barnabas Health
Livingston, New Jersey, United States
Matthew Tremblay, MD
Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Aaron Miller →
Recruiting
University of Rochester Medical Center
Rochester, New York, United States
Andrew Goodman
Recruiting
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, United States
Gabriel Pardo
Recruiting
University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania, United States
Amit Bar-Or
Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Ben Greenberg
Recruiting
the University of Texas Health Science Center at Houston, Mcgovern Medical School
Houston, Texas, United States
John Lindsey, MD
Recruiting
Virginia Commonwealth University School of Medicine
Richmond, Virginia, United States
Myla Goldman, MDRyan Canissario, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ocrelizumab →Placebo for Ocrelizumab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Feb 2023
Primary completion: 1 May 2030
Completion: 1 Nov 2030
Last update posted: 10 Aug 2026
Registered enrollment: 123
Registry id: NCT05285891

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.